The Johns Hopkins University

Randall A Meyer

Jordan J Green

Kelly Rhodes

Jonathan Schneck

Stephany Yi Tzeng

Gregg L Semenza

Qiongyu Guo

Jamie Spangler

Anand Kumar

Jakub Tomala

Derek VanDyke

Giorgio Raimondi

John W Hickey

Corey J Bishop

Alyssa K Galaro

Marcos Iglesias Lozano

The disclosure is directed to a biodegradable particle comprising a polyester or polyester blend, a first protein that binds to an immune cell, and a second protein that promotes proliferation and/or activation of immune cells, and a third soluble protein or small molecule encapsulated within the particle. The second protein is a fusion protein comprising at least a portion of an antibody and at least a portion of a cytokine (i.e., an immunocytokine). The disclosure also is directed to methods for treating a disease or condition in a subject (e.g., an autoimmune disease) comprising administering the aforementioned biodegradable particle to the subject.

Tolerogenic artificial antigen-presenting cells

The present invention provides biodegradable, biomimetic particles for interacting with cells, including immune cells. In various embodiments, the particles comprise a polymer blend comprising a polyester, such as poly(lactic-co-glycolic acid) (PLGA) and a polyamine, such as poly(beta-amino ester) (PBAE). The particles further comprise, on their surface, one or more ligands for one or more cell surface receptor(s) or cell surface molecule(s). In some embodiments, the cell surface receptor or cell surface molecule is on an immune cell, such as a lymphocyte (T cell or B cell), natural killer cell, dendritic cell, or other cell of the immune system or tumor microenvironment.

Biodegradable biomimetic particles

The presently disclosed subject matter provides compositions, methods, and kits comprising shape memory particles that can be used for delivering a drug and/or treating a disease or disorder in a patient. Specifically, shape changes in the presently disclosed shape memory particles can be used to control drug delivery spatially and/or temporally in a patient. Also provided are compositions, methods, and kits comprising nanoparticles and hypoxia-inducible factor (HIF) inhibitors with or without chemotherapeutic agents for inhibiting HIF activity in a patient and/or treating a hypoxia-associated disease or disorder.

Shape memory particles for biomedical uses

Growing community of inventors

Baltimore, MD, United States of America

Randall A Meyer